Xinhua Pharmaceutical: Subsidiary obtained registration certificate for Ursodeoxycholic Acid Capsules.

Xinhua Pharmaceutical announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., recently received the drug registration certificate for Ursodeoxycholic Acid Capsules issued by the National Medical Products Administration. This drug is used to treat gallstones, cholestatic liver disease, and reflux gastritis. The sales of Ursodeoxycholic Acid in public medical institutions in China are expected to be approximately 2.155 billion yuan by 2024.